If a medication is available in the US but not in your country, read When conventional access fails.

Last reviewed 2026-05-01 by Reserve Meds clinical & regulatory team. Saudi Arabia patients access specialty drugs through a specific regulatory framework documented here.

Why Saudi Arabia patients face an access gap in the first place

The Kingdom of Saudi Arabia operates one of the most mature pharmaceutical regulatory frameworks in the GCC. The Saudi Food and Drug Authority (SFDA) maintains the national drug registration list and runs a well-developed named-patient (Personal Importation Program / PIP) framework that has supported access to specialty medicines for over a decade. Saudi Vision 2030 is driving substantial investment in tertiary cancer care, rare disease centers of excellence, and private specialty hospitals — but the gap between FDA-approved availability and KSA market presence remains real for many specialty drugs.

Three patterns of access gap apply across Saudi Arabia:

Registered but not stocked. A drug is on the SFDA list but a particular hospital pharmacy does not have it on hand.
Registered for a different indication. A drug is registered for one indication but the physician is prescribing it for another FDA-approved use that is not locally registered.
Not registered locally at all. A drug is FDA-approved in the United States but the manufacturer has not pursued local registration, often because the patient population is small.

The SFDA (Saudi Food and Drug Authority) named-patient framework

The SFDA Personal Importation Program (PIP) allows a KSA-licensed physician to request import of a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable. The framework explicitly contemplates oncology, rare disease, immunology, and pediatric specialty therapies. The application is filed through the dispensing institution's import pharmacy, with SFDA Drug Sector review.

The application includes:

Clinical justification letter (diagnosis, severity, prior therapies, why this specific drug)
Treating physician's local medical license verification
Patient identifier (anonymized reference preferred)
Product details: brand name, generic name, manufacturer, strength, quantity
Destination dispensing facility license
Chain-of-custody plan from US source to dispensing pharmacy

Approval timelines for routine cases are typically 10-21 business days. Complex cases (rare drug, novel mechanism, off-label use) can extend to 6-10 weeks.

Saudi Arabia's private specialty hospital network

The hospitals that handle named-patient imports as established workflow include: King Faisal Specialist Hospital and Research Centre (KFSH&RC), King Abdulaziz Medical City, Dr. Sulaiman Al Habib Medical Group, Saudi German Hospital, King Saud University Medical City. These institutions have import pharmacy infrastructure and physicians experienced with framework applications. If your treating physician is at a smaller institution without import infrastructure, we can help coordinate with one of these centers.

Saudi Vision 2030 healthcare context

Saudi Vision 2030's healthcare cluster (operated by the Health Sector Transformation Program) is expanding tertiary cancer care, rare disease centers, and digital health infrastructure. While this expansion is shrinking some access gaps, specialty drugs not commercially registered in KSA still require the PIP pathway — the framework remains essential.

Saudization and physician licensing

Saudization (Nitaqat) policies affect the workforce composition at private hospitals; this can sometimes affect approval timelines if a non-Saudi physician's license needs renewal. PIP applications are physician-license-tied, so working with a hospital's medical office to confirm physician licensure status before filing is recommended.

The post-import pharmacovigilance obligation (KSA-specific)

One feature that distinguishes KSA from most GCC peers is the strict post-import pharmacovigilance requirement. The treating physician commits to reporting any adverse event, expected or unexpected, through the SFDA National Pharmacovigilance Centre. This commitment carries through the full course of therapy, not just the initial dose. Reserve Meds' physician documentation kit includes the SFDA AE reporting reference so the treating physician has the framework on hand from day one. We do not file AE reports on behalf of the physician; that obligation is theirs and tied to their SCFHS licence.

Where the pathway works in practice

For physicians outside the major tertiary centres, partnering with an SFDA-licensed specialty importer in Riyadh or Jeddah is the practical route. The importer handles the SFDA filing, the chain-of-custody documentation, and the customs clearance; Reserve Meds aligns with the importer on US-side sourcing and shipment. KFSH&RC, KAMC, MNGHA, KSAU-HS Medical City, and the larger Dr. Sulaiman Al Habib and Saudi German facilities have in-house import pharmacy infrastructure and routinely file directly. Smaller hospitals typically route through an importer.

Real costs: what Saudi Arabia patients actually pay

Costs vary widely by drug. For context, a 30-day supply of a major specialty oral oncology drug (for example, a kinase inhibitor or BTK inhibitor) typically falls in a USD 7,000-13,000 monthly range for the drug itself, plus international logistics (SAR-equivalent of USD 400-1,500 depending on cold chain), plus regulatory documentation handling fees, plus our concierge fee.

For a CAR-T or gene therapy with a list price of USD 400,000-2,000,000, the cost structure changes substantially: the drug dominates everything else. Reserve Meds' role shifts from cost optimization to logistical and regulatory orchestration.

The waitlist form generates an indicative range first, then a transparent firm quote with each line item separated. Nothing is bundled or hidden.

The patient experience: what your family actually does

From the family side, the process looks like this:

Your physician decides this drug is the right next step. That is a clinical decision and stays with them.
Your physician (or the hospital's pharmacy team) reaches out to Reserve Meds, or the patient submits the waitlist request and we connect with the physician.
We confirm eligibility within 24-48 hours and send a documentation kit to your physician.
Your physician fills out the named-patient application and submits it to SFDA.
While the application processes, Reserve Meds aligns the US-side sourcing and shipment plan.
Approval comes through. We ship cold-chain (or ambient, depending on the drug). Your hospital pharmacy receives the medicine.
Your physician initiates therapy.

Common Saudi Arabia-specific questions

Will Bupa Arabia, MedGulf, or Tawuniya cover this?

Each plan handles named-patient imports case-by-case. Some reimburse fully when the medicine is on their formulary even if not stocked, others reimburse a percentage, and many require pre-authorisation. We supply documentation that lets the insurer assess; the claim is yours or your hospital's to file. Cash-pay is the default posture and many KSA patients reimburse themselves later if their plan covers.

Will my MoH-employed physician's letter be sufficient if SFDA flags the case?

Yes. KSA-licensed physicians at MoH-employed positions, KFSH&RC, KAMC, military medical services, and other public-sector institutions have signing authority on PIP applications. The clinical justification letter from your treating physician is the cornerstone of the package. Private-sector physicians at Dr. Sulaiman Al Habib, Saudi German, and other private institutions also have signing authority subject to their institutional license.

What if the drug is a controlled substance?

Reserve Meds does not handle controlled substances (DEA Schedule I-V). Controlled-substance imports require separate regulatory coordination beyond the named-patient framework; we refer those cases to specialists.

Can I receive the drug at home or do I need a hospital?

The dispensing facility must be locally licensed. For oral medicines, a hospital outpatient pharmacy or specialized import pharmacy can dispense. For infusion products, the medicine ships to the infusion center where you will receive it. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.

What about pediatric patients?

The framework applies the same way for pediatric patients. The clinical justification letter typically includes weight-adjusted dosing and pediatric-specific monitoring requirements. The pediatric oncology and rare disease centers in Saudi Arabia handle named-patient imports routinely.

Regional context

KSA's PIP framework is comparable to UAE's MoHAP framework in maturity but typically takes longer (10-21 business days routine vs. 5-15 for UAE). KSA has stronger pharmacovigilance reporting requirements post-import — the dispensing facility must report any adverse events through SFDA's national pharmacovigilance system. This adds operational depth but extends the case-management window.

Where Reserve Meds fits

Reserve Meds is a US-based concierge coordinator. We do not replace your physician, do not replace SFDA, do not replace your dispensing pharmacy. What we do is orchestrate the US-side sourcing, the regulatory documentation kit your physician needs, the international logistics, and a single named coordinator throughout your case.

For specialty oncology, rare disease, immunology, neurology, and other specialty therapies, this orchestration is the difference between an unpredictable ad-hoc process and a predictable, documented cycle.

Add my Saudi Arabia case to the waitlist

This guide is informational, not medical or legal advice. The named-patient framework requires a licensed Saudi Arabia physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.

Drug-access guides for Saudi Arabia

Each guide below is a named-patient access pathway for that specific drug in Saudi Arabia, with real timelines, costs, and the documentation your physician needs. These are coordinated by Reserve Meds for cross-border procurement.

Specialty drug access in Saudi Arabia: the SFDA named-patient pathway